PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 432-440

  Sun, Lei ^a   He, Zhen ^a   Ke, Jia ^a   Li, Senmao ^a   Wu, Xianrui ^a   Lian, Lei ^a   He, Xiaowen ^a   He, Xiaosheng ^a   Hu, Jiancong ^a   Zou, Yifeng ^a   Wu, Xiaojian ^a   Lan, Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

angiogenesis; Colitis associated cancer; Ginkgolide B; PAF; VEGF

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; GINKGOLIDE; GINKGOLIDE B; LACTONE; PLANT EXTRACT; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CHEMICALLY INDUCED; COLITIS; DRUG EFFECTS; FEMALE; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANIMALS; AZOXYMETHANE; CARCINOGENESIS; COLITIS; DEXTRAN SULFATE; FEMALE; GINKGOLIDES; LACTONES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PLATELET ACTIVATING FACTOR;

EID: 84923105757     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mattar MC, Lough D, Pishvaian MJ and Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastroi- ntest Cancer Res 2011; 4: 53-61.
2. Terzic J, Grivennikov S, Karin E and Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114 e2105.
3. Azer SA. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol 2013; 25: 271-281.
4. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999; 103: 3-4.
5. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A and Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-2073.
6. Hatoum OA and Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005; 11: 304-313.
7. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M and Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822-828.
8. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Keough K and Fishman S. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 1999; 44: 424-430.
9. Griga T, Voigt E, Gretzer B, Brasch F and May B. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 1999; 46: 920-923.
10. Chao W and Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993; 292: 617-629.
11. Honda Z, Ishii S and Shimizu T. Platelet-activating factor receptor. J Biochem 2002; 131: 773-779.
12. Eliakim R, Karmeli F, Razin E and Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988; 95: 1167-1172.
13. Sobhani I, Hochlaf S, Denizot Y, Vissuzaine C, Rene E, Benveniste J, Lewin MM and Mignon M. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut 1992; 33: 1220-1225.
14. Wallace JL. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol 1988; 66: 422-425.
15. Camussi G, Montrucchio G, Lupia E, De Martino A, Perona L, Arese M, Vercellone A, Toniolo A and Bussolino F. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995; 154: 6492-6501.
16. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski MR. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995; 96: 940-952.
17. Ko HM, Jung HH, Seo KH, Kang YR, Kim HA, Park SJ, Lee HK and Im SY. Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. FEBS Lett 2006; 580: 3006-3012.
18. Sirois MG and Edelman ER. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol 1997; 272: H2746-2756.
19. Montrucchio G, Sapino A, Bussolati B, Ghisolfi G, Rizea-Savu S, Silvestro L, Lupia E and Camussi G. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 1998; 153: 1589-1596.
20. Robert EG and Hunt JD. Lipid messengers as targets for antiangiogenic therapy. Curr Pharm Des 2001; 7: 1615-1626.
21. Chumanevich AA, Poudyal D, Cui X, Davis T, Wood PA, Smith CD and Hofseth LJ. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010; 31: 1787-1793.
22. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA and Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993; 38: 1722-1734.
23. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP and van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002; 50: 507-512.
24. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM and Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998; 273: 4012-4020.
25. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B and Holvoet P. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J 2000; 14: 2032-2039.
26. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y and Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82: 1983-1991.
27. Kald B, Smedh K, Olaison G, Sjodahl R and Tagesson C. Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn's disease. Digestion 1996; 57: 472-477.
28. Lupia E, Montrucchio G, Battaglia E, Modena V and Camussi G. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996; 26: 1690-1694.
29. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR and Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103: 1611-1620.
30. Yost CC, Weyrich AS and Zimmerman GA. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010; 92: 692-697.
31. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-570.
32. Wang Y, Wang K, Han GC, Wang RX, Xiao H, Hou CM, Guo RF, Dou Y, Shen BF, Li Y and Chen GJ. Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol 2014; 7: 1106-1115.
33. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
34. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S and Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010; 184: 1543-1551.
35. Ahmed A, Dearn S, Shams M, Li XF, Sangha RK, Rola-Pleszczynski M and Jiang J. Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAKpp125. FASEB J 1998; 12: 831-843.
36. Brkovic A and Sirois MG. Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J Cell Biochem 2007; 100: 727-737.
37. Kim HA, Seo KH, Kang YR, Ko HM, Kim KJ, Back HK, Lee HK and Im SY. Mechanisms of platelet-activating factor-induced enhancement of VEGF expression. Cell Physiol Biochem 2011; 27: 55-62.
38. Ma X, Ottino P, Bazan HE and Bazan NG. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004; 45: 2915-2921.
39. Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S and Neurath MF. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010; 207: 2855-2868.